Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: E. Bothos, E. Ntoumou, K. Kelaidoni, D. Roukas, N. Drakoulis, M. Papasavva, F. A. Karakostis, P. Moulos, Karakostis, K.
Format: Dataset
Sprache:eng
Schlagworte:
Biotechnology
Cancer
Cell Biology
Computational Biology
Environmental Sciences not elsewhere classified
FOS: Biological sciences
FOS: Earth and related environmental sciences
FOS: Health sciences
Genetics
Hematology
Infectious Diseases
Medicine
Molecular Biology
Neuroscience
Pharmacology
Physiology
Virology
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.
DOI:10.6084/m9.figshare.14429410